

For Immediate Release

April 9, 2015

Contact:

Mary Kuramoto 513-579-9911 x 2523
m.kuramoto@medpace.com

Medpace Recognized by CenterWatch as a Top Ten CRO in 2015 Global Investigative Site Survey

CINCINNATI, OH — (April 7, 2015) – Medpace Holdings, Inc. announced their selection as a Top Ten CRO in the 2015 CenterWatch Global Investigative Site Survey. CenterWatch surveyed 1900 global sites from October 2014 through January 2015 covering 37 project attributes. Medpace, a global CRO - having conducted studies in 50 plus countries - has rapidly expanded their European presence over the past five years. Seventy two percent of the sites participating in the survey are located in North America and Europe.

Medpace was highly recognized by these sites, scoring “excellent” ratings in two of the most important attributes - professional medical staff, and organization and preparedness in conducting studies. Medpace’s performance in these two areas reflect both the high level of medical expertise that Medpace brings as a strategic partner, and their exacting quality as a result of the Medpace full-service model –a critical part of the Medpace success.

“Medpace has long been regarded as a physician led CRO, embedding medical doctors into each stage of the product lifecycle,” said Todd Meyers, Medpace Vice President. “The Medpace model produces a better result driven by doctors who not only design studies, but deliver the project because they planned it. We are pleased that Medpace continues to be recognized in the industry for excellence as a CRO noted for our ability to plan and execute complex studies.”

ABOUT MEDPACE

Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 50 countries and 6 regions – North America, Europe, Asia Pacific, Latin America, Africa, and the Middle East. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information visit the Medpace website at: www.medpace.com.

###